 | | Vol. 13.19 – 27 May, 2021 |
| |
|
|
| A first genetic hit led to the expansion of pre-leukemic B-cell clones, which were detectable in healthy newborn cord blood. These pre-leukemic clones gave rise to clinically overt leukemia in only about 0.2% of carriers.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
|
| Logistic and negative binomial regression were used to assess the impact of maternal peripheral parasitemia, symptomatic malaria, and placental malaria on cord blood maternal microchimerism.
[The Journal of Infectious Diseases] |
|
|
|
| Researchers compared the effectiveness of conditioned medium of MSCs derived from induced pluripotent stem cells with that derived from umbilical cord MSCs in a mouse cutaneous wound healing model.
[Stem Cell Research & Therapy] |
|
|
|
| Scientists reported human inducible regulatory T cells (iTreg) co-cultured with bone marrow-derived MSCs during short-term ex vivo expansion enhances the stability of iTreg FOXP3 expression and suppressive function in vitro and in vivo, and further that a key mechanism of action is MSC mitochondrial transfer via tunneling nanotubules.
[Scientific Reports] |
|
|
|
| Investigators conducted a multicenter Phase IIa study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after umbilical cord blood transplantation.
[Leukemia & Lymphoma] |
|
|
|
| Retrospective data analysis compared laboratory and clinical outcomes following single-unit umbilical cord blood transplantation performed between 1999 and 2015.
[Transfusion] |
|
|
|
| Scientists proposed that IL-1β influences human umbilical cord Wharton’s jelly derived MSCs migration involving matrix metalloproteinase-3.
[PLOS ONE] |
|
|
|
|
| The authors review the biological mechanisms of endometrial regeneration, and research progress and challenges for adult stem cell therapy for damaged endometrium.
[Molecular Reproduction & Development] |
|
|
|
|
| Sorrento Therapeutics, Inc. announced receipt of clearance from the ANVISA to proceed with a Phase II Pivotal clinical trial of COVI-MSCâ„¢, an injectable infusion of MSCs, for the treatment of hospitalized COVID-19 patients suffering from acute respiratory distress syndrome.
[Sorrento Therapeutics, Inc.] |
|
|
|
|
| June 28 – 29, 2021
Virtual |
|
|
|
|
|
| | University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | Astellas Pharma – Westborough, Massachusetts, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Zhejiang University – Zhejiang, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
